deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT02789345

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy

Sponsor: AstraZeneca

Conditions Non-small Cell Lung Cancer
Interventions Necitumumab Osimertinib Ramucirumab
Updated 22 times since 2017 Last updated: May 23, 2023 Started: Oct 24, 2016 Primary completion: Oct 19, 2017 Completion: May 9, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02789345, this PHASE1 trial focuses on Non-small Cell Lung Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 22 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Jul 2022 · 6 months · monthly snapshot~Jul 2022 – ~Mar 2024 · 20 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

22 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 17 earlier versions

  1. Jul 2022 — Mar 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Jan 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Jan 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  13. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

  14. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE1

  15. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE1

  16. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations